Implications of the oropharyngeal cancer epidemic

Journal of Clinical Oncology

Volumn 29, Issue 32, 2011, Pages 4222-4223

  Mroz, Edmund A ^a   Forastiere, Arlene A ^b   Rocco, James W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CETUXIMAB; CISPLATIN; WART VIRUS VACCINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; CONDYLOMA ACUMINATUM; DRUG EFFICACY; EDITORIAL; EPIDEMIC; HAZARD RATIO; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LONG TERM CARE; MORBIDITY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEROLOGY; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE;

EID: 81155151838     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.8893     Document Type: Editorial

References (27)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294- 4301, 2011
2. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606-2611, 2006 (Pubitemid 46622080)
3. Marur S, D'Souza G, Westra WH, et al.: HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol 11:781-789, 2010
4. Licitra L, Perrone F, Bossi P, et al.: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630-5636, 2006 (Pubitemid 46631302)
5. Ang KK, Harris J, Wheeler R, et al.: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
6. Fakhry C, Westra WH, Li S, et al.: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008 (Pubitemid 351480538)
7. Bhat P, Mattarollo SR, Gosmann C, et al.: Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev 239:85-98, 2011
8. US Food and Drug Administration: Approved products: Gardasil. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042
9. Centers for Disease Control and Prevention (CDC): FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:630-632, 2010
10. Gillison ML, Chaturvedi AK, Lowy DR: HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113:3036-3046, 2008
11. Gillison ML, D'Souza G, Westra W, et al.: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16- negative head and neck cancers. J Natl Cancer Inst 100:407-420, 2008 (Pubitemid 351480511)
12. Marur S, Forastiere AA: Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83:489-501, 2008 (Pubitemid 351536473)
13. Fischer CA, Kampmann M, Zlobec I, et al.: p16 expression in oropharyngeal cancer: Its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 21:1961-1966, 2010
14. Singhi AD, Westra WH: Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 116:2166-2173, 2010
15. ClinicalTrials.gov: Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer. http://clinicaltrials.gov/ct2/show/ NCT01302834
16. Morris LG, Sikora AG, Patel SG, et al.: Second primary cancers after an index head and neck cancer: Subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 29:739-746, 2011
17. Begum S, Cao D, Gillison M, et al.: Tissue distribution of human papillomavirus DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694-5699, 2005
18. Lowy DR, Munger K: Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 363:82-84, 2010
19. Vu HL, Sikora AG, Fu S, et al.: HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 288:149-155, 2010
20. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
21. Brockstein BE, Vokes EE: Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol 8:72-74, 2011
22. Settle K, Posner MR, Schumaker LM, et al.: Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2:776-781, 2009
23. Givens DJ, Karnell LH, Gupta AK, et al.: Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135:1209-1217, 2009
24. Kumar B, Cordell KG, Lee JS, et al.: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008
25. Nichols AC, Finkelstein DM, Faquin WC, et al.: Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res 16:2138-2146, 2010
26. National Cancer Institute: Transforming the NCI's Clinical Trials System. http://transformingtrials.cancer.gov/files/NCI-Presentation-to-Cooperative- Group-Chairs.pdf
27. Institute of Medicine: A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program. Washington, DC, National Academies Press, 2010